What You Should Know:
-Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company’s collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX) to use human genetics and machine learning to improve the discovery and development of new precision medicines.
-The partnership, which began in 2018, was previously extended in 2021. The collaboration will now run until 2026.
Vertex and
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Bluesight Diversion Trends Report Reveals $38M Lost to Drug Waste
What You Should Know:
- Bluesight, a provider of medication intelligence solutions, released its 2024 Diversion Trends Report, offering valuable insights for healthcare providers to improve controlled substance monitoring and patient safety.
- The report demonstrates progress in healthcare's fight against controlled substance diversion. However, the data also highlights areas for continued improvement, particularly in waste management and medication documentation.
The report
Read More
Cognizant and Yseop Partner to Deliver GenAI Medical Writing for Life Sciences
What You Should Know:
- Cognizant and Yseop, a leading AI software company, have joined forces to accelerate and streamline scientific content creation in the biopharmaceutical industry.
- The strategic partnership leverages Yseop Copilot, a generative AI tool, to transform medical writing, enhance productivity, and expedite the delivery of life-saving treatments.
Challenges of Traditional Medical Writing
The current process for creating scientific content is a
Read More
Uncapping Capacity: Solving for Technology Overload in Clinical Trials
The clinical trial landscape has greatly benefited from technological innovations over the past few decades. Innovation has expanded remote monitoring capabilities, patient recruitment tactics and the decentralization of clinical trials. However, one of the greatest hurdles that clinical researchers are currently facing is a deluge of disparate solutions across the clinical trial workflow. For example, surveys reveal that 60% of clinical research sites are using up to, and over, 20 systems on a
Read More
Verantos Launches Alzheimer’s Disease Pragmatic Registry to Support RWE Generation
What You Should Know:
- Verantos, the global leader in high-validity real-world evidence at scale, has launched its Alzheimer’s Disease Pragmatic Registry.
- This registry offers life sciences organizations rich and reliable data on patients with Alzheimer’s disease and related conditions.
Verantos: Leading High-Validity Real-World Evidence
Verantos is the global leader in high-validity real-world evidence at scale. By applying artificial intelligence to comprehensive patient
Read More
Tasso & InnoVero to Supply Anti-Doping Test to 2024 Paris Olympics, Expanded Partnership
What You Should Know:
- InnoVero, a global leader in providing innovative, athlete-centric collection technologies to anti-doping organizations worldwide and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the extension of their partnership that was first initiated in 2021.
- In addition to collaboratively developing new athlete-centric solutions, InnoVero will continue to serve as the exclusive worldwide distributor of Tasso
Read More
Courier Health Raises $16.5M for First Patient CRM for Biopharma
What You Should Know:
- Courier Health, a technology company transforming patient experiences in the life sciences industry raises $16.5M in Series A funding led by Norwest Venture Partners with participation from existing investor Work-Bench.
- The investment fuels Courier Health's mission to provide biopharma companies with the tools to manage and personalize the patient journey for life-altering therapies.
Addressing the Rise of Specialty Medicines
The landscape of
Read More
Pangea Biomed’s ENLIGHT-DP Predicts Cancer Treatment Response from Simple Scans
What You Should Know:
- Pangea Biomed, a leader in precision oncology, announced a significant breakthrough in its ENLIGHT cancer response predictor. A new study published in Nature Cancer demonstrates the effectiveness of their ENLIGHT-DP platform, revealing its ability to predict cancer treatment response across various types and drugs using only routine pathology slides.
- While these findings are promising, further validation and testing are planned for regulatory
Read More
Biopharma at a Crossroads: AI Offers Key to R&D Reinvention
What You Should Know:
- A new report by Accenture, "Reinventing R&D in the Age of AI," paints a clear picture: the biopharmaceutical industry stands at a critical juncture. Companies that embrace intelligent technologies like AI and machine learning are poised to become the future's leaders, while those clinging to outdated methods risk falling behind.
- Accenture's report serves as a roadmap, offering valuable insights and practical steps for companies ready to embrace the
Read More
VenoStent Raises $20M for Dialysis Solution, Secures $3.6M NIH Grant for U.S. Dialysis Therapeutic Clinical Trial
What You Should Know:
- VenoStent, Inc., a medical device company pioneering a new approach to improve dialysis patient outcomes, announced the successful completion of its Series A funding round. The round closed at $20M, with Norwest Venture Partners contributing an additional $4M to join Good Growth Capital and IAG Capital Partners as co-leads.
- VenoStent also welcomes Dr. Zack Scott, Norwest General Partner, and Dr. Ehi Akhirome, Norwest Investor, to its board of
Read More
